Vktx nasdaq.

Here are three undervalued biotech stocks to consider immediately. CRISPR Therapeutics (CRSP): It could soon bring Exa-cel to market with Vertex Pharmaceuticals. Viking Therapeutics ( VKTX ): A ...VKTX (U.S.: Nasdaq) Overview Profile FinancialsNASDAQ: VKTX · IEX Real-Time Price · USD. Add to Watchlist 12.02-0.26 (-2.16%) Nov 27, 2023, 12:50 PM EST - Market open. Overview; Financials; ... Stock Price Forecast. According to 11 stock analysts, the average 12-month stock price forecast for VKTX stock stock is $29.36, which predicts an increase of 144.36%. The lowest target is …Mar 16, 2023 · VKTX has move up from $4.00 a share to nearly $11.00 a share, largely in sympathy since those Madrigal trial results were announced. Therefore, I have taken profits on most of my small stake in VKTX. During the last session, Viking Therapeutics Inc (NASDAQ:VKTX)’s traded shares were 1.77 million, with the beta value of the company hitting 0.59. At the end of the trading day, the stock’s price was $12.22, reflecting an intraday gain of 3.30% or $0.39. The 52-week high for the VKTX share is $ ...

Based on analysts offering 12 month price targets for VKTX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . Viking Therapeutics (NASDAQ:VKTX) is arguably best known for being one of the frontrunners to win the "NASH Dash," i.e. the first company to secure approval to market and sell a drug designed to ...A high-level overview of Viking Therapeutics, Inc. (VKTX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

View real-time VKTX stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ...

As of February 3, 2023, the average one-year price target for Viking Therapeutics is $18.70. The forecasts range from a low of $11.11 to a high of $31.50. The average price target represents an ... In trading on Tuesday, shares of Viking Therapeutics Inc (Symbol: VKTX) entered into oversold territory, hitting an RSI reading of 25.3, after changing hands as low as $15.06 per share. By ...VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 83% based on the firm’s underlying fundamentals and the stock ...3,698,369. 784,592. 4.713748. Back to VKTX Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid ...

Market Cap. $1.3B. Currency in USD. Quote data delayed by at least 15 minutes.

Viking Therapeutics (VKTX 4.42%), a small-cap biotech, has been on quite the ride over the past few months.Thanks to a positive late-stage trial in nonalcoholic steatohepatitis (NASH) from rival ...

VKTX Viking Therapeutics Options Ahead of Earnings Analyzing the options chain and the chart patterns of VKTX Viking Therapeutics prior to the earnings report this week, I would consider purchasing the 11usd strike price Calls with an expiration date of 2024-1-19, for a premium of approximately $1.80. View real-time VKTX stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ...EPS Estimate Trends. Current. N/A. 1 Month Ago. -$0.24. 3 Months Ago. -$0.24. Viking Therapeutics Inc. analyst estimates, including VKTX earnings per share estimates and analyst recommendations.At Stock Options Channel, our YieldBoost formula has looked up and down the VKTX options chain for the new August 11th contracts and identified one put and one call contract of particular interest ...Shares of the clinical-stage metabolic disorder specialist Viking Therapeutics ( VKTX 7.03%) were down by 6.45% on moderate volume as of 1:42 p.m. ET Thursday afternoon. The drugmaker's shares are ...

In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), with a price target of $35.00.The company’s shares opened ...Viking Therapeutics (NASDAQ: VKTX) has had a very promising 2023.They announced very good early results for an obesity drug in March. They then quickly used those good results to sell $250 million ...Fintel reports that on May 3, 2023, Roth MKM maintained coverage of Viking Therapeutics (NASDAQ:VKTX) with a Buy recommendation.. Analyst Price Forecast Suggests 31.63% Upside. As of April 24 ...March 29, 2023 at 11:12 AM · 4 min read. Shares of Viking Therapeutics VKTX have surged almost 70% on Mar 28, after it announced positive clinical data of VK2735, a novel dual agonist of the ...View Viking Therapeutics, Inc VKTX investment & stock information. Get the latest Viking Therapeutics, Inc VKTX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Nasdaq Futures. 15,979.75 ... (NASDAQ:VKTX), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the …Viking Therapeutics Inc ( NASDAQ:VKTX) reported a strong quarter-end cash position of $376M. The company's net loss for Q3 2023 was $22.5 million, or $0.23 per share, compared to a net loss of $15 ...

The company is Viking Therapeutics ( NASDAQ: VKTX) which was basically offering a lower valuation as compared to other stocks in the NASH-related biotech field. Picking two competitors for example ...Jul 10, 2023 · Below is Validea's guru fundamental report for VIKING THERAPEUTICS INC (VKTX). Of the 22 guru strategies we follow, VKTX rates highest using our Quantitative Momentum Investor model based on the ...

VKTX has move up from $4.00 a share to nearly $11.00 a share, largely in sympathy since those Madrigal trial results were announced. Therefore, I have taken profits on most of my small stake in VKTX.Nov 21, 2023 · VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 55% based on the firm’s underlying fundamentals and the stock ... Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. -18.74M. -233.36%. Get the latest 89bio Inc (ETNB) real-time quote, historical ...(NASDAQ: VKTX) Viking Therapeutics's market cap is $978.28M, as of Nov 12, 2023. Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares. Viking Therapeutics 's market cap is calculated by multiplying VKTX 's current stock price of $9.78 by VKTX 's total outstanding shares of 100,028,953 .About Latest Pre-Market Trades. Nasdaq provides market information opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. See Also. Nasdaq MarketSIte. Do Not Sell My Personal ... 3,698,369. 784,592. 4.713748. Back to VKTX Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid ...Since the year began, shares of Viking Therapeutics (NASDAQ:VKTX) exploded from about $8 to about $25 a share.All thanks to its potential treatment for obesity, VK2735. So far, we know it works ...Dec 4, 2023 · The latest price target for Viking Therapeutics (NASDAQ: VKTX) was reported by Truist Securities on December 4, 2023.The analyst firm set a price target for $32.00 expecting VKTX to rise to within ... VKTX Latest Real Time Trades ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, and more asset classes. /Dec 4, 2023 · The public float for VKTX is 89.39M and currently, short sellers hold a 18.98% ratio of that float. The average trading volume of VKTX on December 04, 2023 was 2.05M shares. VKTX) stock’s latest price update. Viking Therapeutics Inc (NASDAQ: VKTX)’s stock price has plunge by 9.99relation to previous closing price of 13.01.

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of new results from the ongoing Phase 2b clinical trial of VK2809, the company's novel liver-selective thyroid hormone receptor beta ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) is a good speculative biotech play to look into. That's because it just recently released positive results from its phase 2b VOYAGE study, ...

A high-level overview of Viking Therapeutics, Inc. (VKTX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Find the latest dividend history for Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com.Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP agonist compound VK2735 for the ...Research Viking Therapeutics' (Nasdaq:VKTX) stock key valuation metrics while comparing it with its industry peers & market side by side. Dashboard Markets Discover Watchlist Portfolios Screener Viking Therapeutics, Inc.Next on this list of stocks that analysts love is Viking Therapeutics (NASDAQ: VKTX ). The stock has been rated by 11 analysts in the last three months with 10 of them giving VKTX stock a Strong ...Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock. SAN DIEGO , March 29, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic a... 8 months ago - PRNewsWire.Viking Therapeutics Inc (NASDAQ: VKTX) shares are trading higher Tuesday after the company presented new data from its Phase 2b studyViking Therapeutics Inc (NASDAQ: VKTX) shares are trading higher Tuesday after the company reported results from its Phase 1 trial of VK2735 for the potential treatment ofViking Therapeutics Inc ( NASDAQ:VKTX) reported a strong quarter-end cash position of $376M. The company's net loss for Q3 2023 was $22.5 million, or $0.23 per share, compared to a net loss of $15 ...Feb 9, 2023 · Average portfolio weight of all funds dedicated to VKTX is 0.02%, a decrease of 20.95%. Total shares owned by institutions decreased in the last three months by 1.25% to 27,896K shares. Viking Therapeutics Inc ( NASDAQ:VKTX) reported a strong quarter-end cash position of $376M. The company's net loss for Q3 2023 was $22.5 million, or $0.23 per share, compared to a net loss of $15 ...Real time Viking Therapeutics (VKTX) stock price quote, stock graph, news & analysis.

Price Volume Sep '23 Oct '23 Nov '23 Dec '23 $10 $8 $12 $14 $16 $18 0M 10M 20M 2020. Display Events. Dividends. Splits. Earnings. News. Chart Style. Line. Mountain.Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have received an average rating of “Buy” from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. Nine analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have covered the stock in the […]Viking Therapeutics Inc. VKTX (U.S.: Nasdaq) Overview Profile FinancialsViking Therapeutics Inc ( NASDAQ:VKTX) reported a strong quarter-end cash position of $376M. The company's net loss for Q3 2023 was $22.5 million, or $0.23 per share, compared to a net loss of $15 ...Instagram:https://instagram. buy bank stockswhich platform is best for forex tradingplain all american pipelinealt investment platform In trading on Tuesday, shares of Viking Therapeutics Inc (Symbol: VKTX) entered into oversold territory, hitting an RSI reading of 25.3, after changing hands as low as $15.06 per share. By ...Find the latest Earnings Report Date for Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com. best day trading laptopmetatrader stock broker EPS Estimate Trends. Current. N/A. 1 Month Ago. -$0.24. 3 Months Ago. -$0.24. Viking Therapeutics Inc. analyst estimates, including VKTX earnings per share estimates and analyst recommendations.VKTX VKTX AFTER HOURS QUOTE VKTX LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ... how to day trade with robinhood The company is Viking Therapeutics ( NASDAQ: VKTX) which was basically offering a lower valuation as compared to other stocks in the NASH-related biotech field. Picking two competitors for example ...Find the latest Madrigal Pharmaceuticals, Inc. (MDGL) stock quote, history, news and other vital information to help you with your stock trading and investing.Find the latest Earnings Report Date for Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com.